The US FDA is using its guidance-writing powers to reshape the look of oncology clinical trials, with the goal of streamlining and modernizing cancer drug development in order to foster a more patient-focused approach.
In the past three months, the agency has issued draft guidance documents aimed at expanding the ages of cancer patients eligible for clinical trials, giving sponsors more flexibility in designing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?